Aug. 10 at 10:13 PM
$ORGO I am debating if I take a short here (probably if it is pushed near
$5), many critical negatives:
-Huge dilution can hit anytime from the outstanding preferred shares that would add 36M shares to the float.
-Big misses on revenue and EPS, yet again.
-Major downgrade to 2025 profitability on EPS and EBIDTA measures and weaker revenue guidance than consensus.
-Massive cash burn near -37M in Q2 alone with plummeting cash.
-Whatever product is in phase 3 trial, it won't be approved till 2027, if ever, and won't contribute to growth in a long time.
-Short interest is heavy and increasing steadily.
